Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2016, Article ID 6723575, 3 pages
http://dx.doi.org/10.1155/2016/6723575
Case Report

A Tongue Lesion as a Sign of a Systemic Disease

1Third Department of Medical Oncology, Hygeia Hospital, 15123 Athens, Greece
2Johns Hopkins University Internship Program, Baltimore, MD 21218, USA
3Intensive Care Unit, Hygeia Hospital, 15123 Athens, Greece
4First Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece
5Department of Otolaryngology, Hygeia Hospital, 15123 Athens, Greece
6Department of Pathology, Hygeia Hospital, 15123 Athens, Greece

Received 22 October 2015; Revised 4 January 2016; Accepted 10 January 2016

Academic Editor: Mamede de Carvalho

Copyright © 2016 Chrysoula I. Liakou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Desport, F. Bridoux, C. Sirac et al., “AL amyloidosis,” Orphanet Journal of Rare Diseases, vol. 7, article 54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Andreadis, A. Poulopoulos, P. Papadopoulos, and A. Epivatianos, “Localized tongue amyloidosis in a patient with neurofibromatosis type II,” Head and Neck Pathology, vol. 5, no. 3, pp. 302–305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. H. J. Lachmann, D. R. Booth, S. E. Booth et al., “Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis,” The New England Journal of Medicine, vol. 346, no. 23, pp. 1786–1791, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. K. B. Shah, Y. Inoue, and M. R. Mehra, “Amyloidosis and the heart: a comprehensive review,” Archives of Internal Medicine, vol. 166, no. 17, pp. 1805–1813, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. X. Huang, Q. Wang, S. Jiang, W. Chen, C. Zeng, and Z. Liu, “The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients,” Clinical Kidney Journal, vol. 8, no. 1, pp. 120–126, 2015. View at Publisher · View at Google Scholar
  6. V. Sanchorawala, “Light-chain amyloidosis (AL): diagnosis and treatment,” Clinical Journal of the American Society of Nephrology, vol. 1, pp. 1331–1341, 2006. View at Google Scholar
  7. R. S. Abraham, J. A. Katzmann, R. J. Clark, A. R. Bradwell, R. A. Kyle, and M. A. Gertz, “Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis,” American Journal of Clinical Pathology, vol. 119, no. 2, pp. 274–278, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Katzmann, R. J. Clark, R. S. Abraham et al., “Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains,” Clinical Chemistry, vol. 48, no. 9, pp. 1437–1444, 2002. View at Google Scholar
  9. S. K. Kumar, M. A. Gertz, M. Q. Lacy et al., “Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score,” Mayo Clinic Proceedings, vol. 86, no. 1, pp. 12–18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. W. Werning, Oral Cancer, Thieme Medical Publishers, 2007.
  11. P. D. Gorevic, “Amyloid and inflammation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 41, pp. 16291–16292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Mahmood, G. Palladini, V. Sanchorawala, and A. Wechalekar, “Update on treatment of light chain amyloidosis,” Haematologica, vol. 99, no. 2, pp. 209–221, 2014. View at Publisher · View at Google Scholar · View at Scopus